中华放射肿瘤学杂志
中華放射腫瘤學雜誌
중화방사종류학잡지
CHINESE JOURNAL OF RADIATION ONCOLOGY
2013年
2期
108-110
,共3页
帕丽达·阿皮孜阿吉%伊斯刊达尔·阿布力米提%张瑾熔
帕麗達·阿皮孜阿吉%伊斯刊達爾·阿佈力米提%張瑾鎔
파려체·아피자아길%이사간체이·아포력미제%장근용
食管肿瘤/放射疗法%X射线修复交叉互补基因3%人8-羟基鸟嘌呤糖苷酶1%预后
食管腫瘤/放射療法%X射線脩複交扠互補基因3%人8-羥基鳥嘌呤糖苷酶1%預後
식관종류/방사요법%X사선수복교차호보기인3%인8-간기조표령당감매1%예후
Esophageal neoplasms/radiotherapy%X-ray repair cross complementing gene 3%Human 8-hydroxy guanine glycosidase 1%Prognosis
目的 探讨食管鳞状细胞癌(ESCC)癌组织中X射线修复交叉互补基因3(XRCC3)和人类8-羟基鸟嘌呤糖苷酶1(HOGG1)的蛋白表达与ESCC放疗预后相关性.方法 采用免疫组织化学SP法检测治疗前171例ESCC组织标本中XRCC1、HOGG1蛋白表达.Kaplan-Meier法生存分析并Logrank法检验表达阴、阳性间生存差异,Cox模型多因素预后分析.结果 随访率为87.2％,其中随访时间满1、2、3年者分别为140、136、129例.XRCC3主要表达于细胞核,HOGG1主要表达于细胞核与线粒体,两者符合程度达72.5％(x2=23.94,P=0.000).XRCC3表达阳、阴性的近期疗效相似(x2 =0.98,P=0.614),生存率也相似,中位生存期均为54个月(x2=0.17,P=0.683),HOGG1表达阳、阴性近期疗效相似(x2=0.26,P =0.880),生存率也相似,中位生存期均为49个月(x2=0.08,P =0.780).多因素分析结果显示疗效评价、病变长度与ESCC预后相关(x2=7.99、3.76,P=0.005、0.045).结论 XRCC3、HOGG1的蛋白表达与ESCC放疗预后可能无关.
目的 探討食管鱗狀細胞癌(ESCC)癌組織中X射線脩複交扠互補基因3(XRCC3)和人類8-羥基鳥嘌呤糖苷酶1(HOGG1)的蛋白錶達與ESCC放療預後相關性.方法 採用免疫組織化學SP法檢測治療前171例ESCC組織標本中XRCC1、HOGG1蛋白錶達.Kaplan-Meier法生存分析併Logrank法檢驗錶達陰、暘性間生存差異,Cox模型多因素預後分析.結果 隨訪率為87.2％,其中隨訪時間滿1、2、3年者分彆為140、136、129例.XRCC3主要錶達于細胞覈,HOGG1主要錶達于細胞覈與線粒體,兩者符閤程度達72.5％(x2=23.94,P=0.000).XRCC3錶達暘、陰性的近期療效相似(x2 =0.98,P=0.614),生存率也相似,中位生存期均為54箇月(x2=0.17,P=0.683),HOGG1錶達暘、陰性近期療效相似(x2=0.26,P =0.880),生存率也相似,中位生存期均為49箇月(x2=0.08,P =0.780).多因素分析結果顯示療效評價、病變長度與ESCC預後相關(x2=7.99、3.76,P=0.005、0.045).結論 XRCC3、HOGG1的蛋白錶達與ESCC放療預後可能無關.
목적 탐토식관린상세포암(ESCC)암조직중X사선수복교차호보기인3(XRCC3)화인류8-간기조표령당감매1(HOGG1)적단백표체여ESCC방료예후상관성.방법 채용면역조직화학SP법검측치료전171례ESCC조직표본중XRCC1、HOGG1단백표체.Kaplan-Meier법생존분석병Logrank법검험표체음、양성간생존차이,Cox모형다인소예후분석.결과 수방솔위87.2％,기중수방시간만1、2、3년자분별위140、136、129례.XRCC3주요표체우세포핵,HOGG1주요표체우세포핵여선립체,량자부합정도체72.5％(x2=23.94,P=0.000).XRCC3표체양、음성적근기료효상사(x2 =0.98,P=0.614),생존솔야상사,중위생존기균위54개월(x2=0.17,P=0.683),HOGG1표체양、음성근기료효상사(x2=0.26,P =0.880),생존솔야상사,중위생존기균위49개월(x2=0.08,P =0.780).다인소분석결과현시료효평개、병변장도여ESCC예후상관(x2=7.99、3.76,P=0.005、0.045).결론 XRCC3、HOGG1적단백표체여ESCC방료예후가능무관.
Objective To investigate the relationship between the protein expression of X-ray repair cross-complementing protein 3 (XRCC3) and human 8-hydroxyguanine glycosylase 1 (HOGG1) in esophageal squamous cell carcinoma (ESCC) tissue and the prognosis in ESCC patients after radiotherapy.Methods Immunohistochemical SP method was used to measure the protein expression of XRCC3 and HOGG1 in 171 ESCC tissue samples before radiotherapy.The Kaplan-Meier method was used for survival analysis,and the logrank test was used for analyzing the survival difference between negative and positive samples.The Cox model was used for multivariate prognostic analysis.Results The follow-up rate was 87.2％ ; 140 patients were followed up for at least 1 year,136 patients for at least 2 years,and 129 patients for at least 3 years.XRCC3 was mainly expressed in the nucleus,and HOGG1 was mainly expressed in the nucleus and mitochondria,with a coincidence degree of 72.5％ (x2 =23.94,P =0.000).The patients with positive XRCC3 expression and negative XRCC3 expression had similar short-term responses (x2 =0.98,P =0.614)as well as similar survival rates,and both patient groups had a median survival time of 54 months (x2 =0.17,P =0.683).The patients with positive HOGG1 expression and negative HOGG1 expression had similar short-term responses (x2 =0.26,P =0.880) as well as similar survival rates,and both patient groups had a median survival time of 49 months (x2 =0.08,P =0.780).The multivariate prognostic analysis showed that the response evaluation and tumor length were related to the prognosis of ESCC (x2 =7.99,P =0.005 ; x2 =3.76,P =0.045).Conclusions The protein expression of XRCC3 and HOGG1 may be unrelated to the prognosis of ESCC after radiotherapy.
